Global Lung Cancer Therapeutics Market Report and Forecast 2023-2031

Global Lung Cancer Therapeutics Market Report and Forecast 2023-2031


Global Lung Cancer Therapeutics Market Outlook


The global lung cancer therapeutics market size attained a value of USD 28.6 billion in 2022. The market is likely to grow at a CAGR of 11.60% during the forecast period of 2023-2031 to attain a value of USD 76.9 billion by 2031.

Lung Cancer Therapeutics Market: Introduction


The lung cancer therapeutics market encompasses a wide range of treatments, medications, and therapies developed to manage and treat lung cancer, one of the most prevalent and deadly types of cancer worldwide. Lung cancer is primarily categorized into two major types: non-small cell lung cancer (NSCLC), accounting for approximately 85% of cases, and small cell lung cancer (SCLC), accounting for the remaining 15%. The high incidence of lung cancer, coupled with its aggressive nature and high mortality rate, has led to a growing focus on the development of innovative and effective therapeutic options to combat this disease.

The lung cancer therapeutics market comprises various treatment modalities, including chemotherapy, targeted therapy, immunotherapy, and radiation therapy. Chemotherapy has been the mainstay of lung cancer treatment for several years, involving the use of cytotoxic drugs that destroy rapidly dividing cancer cells. However, advancements in our understanding of the molecular mechanisms underlying lung cancer have led to the development of targeted therapies and immunotherapies that are more specific and less toxic than traditional chemotherapy.

Targeted therapies involve the use of drugs that specifically target cancer cells by blocking the growth and survival pathways on which these cells depend. These therapies have shown promise in treating patients with specific genetic mutations, such as EGFR (epidermal growth factor receptor) and ALK (anaplastic lymphoma kinase) mutations, which are more common in NSCLC.

Immunotherapy is another rapidly evolving treatment option in the Lung Cancer Therapeutics market. Immunotherapies work by enhancing the body's immune system to recognize and attack cancer cells. Some of the most promising immunotherapies for lung cancer are checkpoint inhibitors, which block proteins that prevent the immune system from attacking cancer cells, such as PD-1 (programmed cell death protein 1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4).

Radiation therapy, another treatment modality, uses high-energy radiation to kill cancer cells and shrink tumours. It can be administered externally or internally and is often used in combination with other therapies, such as chemotherapy or surgery, to improve treatment outcomes.

As the incidence of lung cancer continues to rise, there is a growing need for novel and effective therapeutics to improve patient survival and quality of life. The Lung Cancer Therapeutics market is expected to witness significant growth in the coming years, driven by factors such as advancements in molecular biology, the increasing adoption of targeted therapies and immunotherapies, and a continued focus on research and development in the field of oncology.

Lung Cancer Therapeutics Market Segmentations


The market can be categorised into segments like cancer type, therapy, therapy type, end user, distribution channel, and region.

Market Breakup by Cancer Type
  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer (SCLC)
  • Metastatic Lung Cancer
  • Mesothelioma
  • Others
Market Breakup by Therapy
  • Chemotherapy
  • Immunotherapy
  • Radiation Therapy
  • Targeted Therapy
  • Others
Market Breakup by Therapy type
  • Single Drug Therapy
  • Combination Therapy
Market Breakup by End User
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
Market Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
Lung Cancer Therapeutics Market Breakup by Region
  • North America
  • United States of America
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Lung Cancer Therapeutics Market Scenario


The global lung cancer therapeutics market has been experiencing substantial growth in recent years, driven by factors such as the increasing prevalence of lung cancer, advancements in treatment options, rising healthcare expenditure, and a growing focus on personalized medicine. The market is expected to continue expanding as pharmaceutical companies, researchers, and healthcare providers collaborate to develop and implement innovative and effective therapies to address this critical health issue.

One of the primary drivers of the lung cancer therapeutics market is the rising incidence of lung cancer worldwide. As the leading cause of cancer-related deaths, lung cancer places a significant burden on healthcare systems and patients, necessitating the development of novel treatments and therapies to improve survival rates and quality of life. This growing need for effective lung cancer therapies has fueled significant investment in research and development, leading to the discovery and approval of several new drugs and treatment modalities in recent years.

Advancements in our understanding of the molecular mechanisms underlying lung cancer have played a crucial role in the growth of the lung cancer therapeutics market. The identification of specific genetic mutations and biomarkers has led to the development of targeted therapies and immunotherapies that are more specific and less toxic than traditional chemotherapy. These new treatment options have shown promising results in clinical trials and have transformed the landscape of lung cancer treatment, particularly for patients with specific genetic profiles.

The increasing adoption of personalized medicine in cancer treatment is another factor driving the growth of the lung cancer therapeutics market. Personalized medicine involves tailoring treatment strategies to individual patients based on their unique genetic makeup, disease profile, and other factors. In the context of lung cancer, personalized medicine has facilitated the development and implementation of targeted therapies and immunotherapies that are more effective and have fewer side effects than traditional treatments. As the field of personalized medicine continues to advance, the demand for innovative and tailored lung cancer therapies is expected to rise further.

Despite the overall positive outlook for the lung cancer therapeutics market, there are some challenges that may impact its growth. These include the high cost of novel therapies, limited access to advanced treatments in certain regions, and the emergence of drug resistance in some patients. However, ongoing research and development efforts, coupled with the growing emphasis on personalized medicine and the increasing need for effective lung cancer treatments, are expected to drive the market's growth in the coming years, leading to the discovery and implementation of innovative therapies that improve patient outcomes and survival rates.

Key Players in the Global Lung Cancer Therapeutics Market


The report gives an in-depth analysis of the key players involved in the lung cancer therapeutics market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • Genentech, Inc.
  • AstraZeneca PLC
  • Novartis AG
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd
  • Boehringer Ingelheim International GmbH
  • Agennix AG
  • Eli Lilly and Company
  • Sanofi-Aventis
  • GlaxoSmithKline
  • Hoffman-La Roche
*Please Note:* The report will be completed in 7 business days after order confirmation


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Lung Cancer Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Lung Cancer Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Lung Cancer Epidemiology (2016-2031)
5.3 Europe Lung Cancer Epidemiology (2016-2031)
5.4 Asia-Pacific Lung Cancer Epidemiology (2016-2031)
5.5 Latin America Lung Cancer Epidemiology (2016-2031)
5.6 Middle East & Africa Lung Cancer Epidemiology (2016-2031)
6 Global Lung Cancer Therapeutics Market Overview
6.1 Global Lung Cancer Therapeutics Market Historical Value (2016-2022)
6.2 Global Lung Cancer Therapeutics Market Forecast Value (2023-2031)
7 Global Lung Cancer Therapeutics Market Landscape
7.1 Global Lung Cancer Therapeutics Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Lung Cancer Therapeutics Product Landscape
7.2.1 Analysis by Cancer Type
7.2.2 Analysis by Therapy
7.2.3 Analysis by End User
8 Lung Cancer Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Lung Cancer Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Lung Cancer Therapeutics Market Segmentation
11.1 Global Lung Cancer Therapeutics Market by Cancer Type
11.1.1 Market Overview
11.1.2 Non-Small Cell Lung Cancer
11.1.3 Small Cell Lung Cancer (SCLC)
11.1.4 Metastatic Lung Cancer
11.1.5 Mesothelioma
11.1.6 Others
11.2 Global Lung Cancer Therapeutics Market by Therapy
11.2.1 Market Overview
11.2.2 Chemotherapy
11.2.3 Immunotherapy
11.2.4 Radiation Therapy
11.2.5 Targeted Therapy
11.2.6 Others
11.3 Global Lung Cancer Therapeutics Market by Therapy Type
11.3.1 Market Overview
11.3.2 Single Drug Therapy
11.3.3 Combination Therapy
11.4 Global Lung Cancer Therapeutics Market by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Homecare
11.4.4 Specialty Clinics
11.4.5 Others
11.5 Global Lung Cancer Therapeutics Market by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospital Pharmacy
11.5.3 Retail Pharmacy
11.5.4 Online Pharmacy
11.6 Global Lung Cancer Therapeutics Market by Region
11.6.1 Market Overview
11.6.2 North America
11.6.3 Europe
11.6.4 Asia Pacific
11.6.5 Latin America
11.6.6 Middle East and Africa
12 North America Lung Cancer Therapeutics Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Lung Cancer Therapeutics Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Lung Cancer Therapeutics Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Lung Cancer Therapeutics Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Lung Cancer Therapeutics Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Regulatory Framework
22.1 Regulatory Overview
22.1.1 US FDA
22.1.2 EU EMA
22.1.3 INDIA CDSCO
22.1.4 JAPAN PMDA
22.1.5 Others
23 Supplier Landscape
23.1 Genentech, Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 AstraZeneca PLC
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Novartis AG
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Merck KGaA
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 F. Hoffmann-La Roche Ltd
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Boehringer Ingelheim International GmbH
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Agennix AG
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Eli Lilly and Company
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Sanofi-Aventis
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 GlaxoSmithKline
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Hoffman-La Roche
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
24 Global Lung Cancer Therapeutics Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings